Jefferies analyst Matthew Taylor maintained a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $100.00. The ...

Diabetes is a chronic, life-threatening disease for which there is no known cure. DexCom’s CGM system is superior to traditional finger-stick tests because it provides users with continuous data ...

Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share. Read More on DXCM: DexCom NewsMORE Related Stocks Indices Commodities ...

Part of a broader initiative between the two companies to “develop and market products to help people better manage their diabetes”, Dexcom G5 Mobile users will now be able to sync their CGM ...

DexCom's Q3 results showed disappointing 2% revenue growth and a 26% decline in operating income. Click here to read my DXCM ...

DexCom Inc. DXCM recently announced the launch of its latest continuous glucose monitoring (CGM) system, Dexcom ONE+. This system is simple to use and lowers the entry hurdle to diabetic technology.

This current is read by the system and used to calculate an estimate of the blood glucose concentration based on a calibration curve. But while the chemistry is straightforward, human biology and ...

Medtech giants Dexcom and Abbott tied up with insulin pump maker Insulet in separate partnerships that involve integrating Insulet's Omnipod insulin delivery system with their continuous glucose ...

DexCom ( NASDAQ:DXCM ) Third Quarter 2024 Results Key Financial Results Revenue: US$994.2m (up 2.0% from 3Q 2023). Net... Dexcom stock closed in the red on Friday after the diabetes devices player ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...